Influenza A virus subtype H1N1

SINOVAC Beijing Settled Litigation of Its Business License and Seals

Retrieved on: 
Friday, December 3, 2021
Biotechnology, Health, Professional Services, Pharmaceutical, Legal, Hepatitis A, Government, EV71, Influenza A virus subtype H1N1, Seals, Private Securities Litigation Reform Act, Chickenpox, Forward-looking statement, Company, Sinovac Biotech, WHO, Vaccine, COVID-19, Program, Mumps, Research, Terminology, H5N1, Infection, Chinese government award for outstanding self finance students abroad, Court, NASDAQ

SINOVAC Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, announced the Companys subsidiary SINOVAC Biotech Co., Ltd (SINOVAC Beijing) settled the litigation with Mr. Aihua Pan concerning its business license and seals.

Key Points: 
  • SINOVAC Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, announced the Companys subsidiary SINOVAC Biotech Co., Ltd (SINOVAC Beijing) settled the litigation with Mr. Aihua Pan concerning its business license and seals.
  • Mr. Pan subsequently obtained a re-issued business license of SINOVAC Beijing based on the false claim.
  • : 1101081347485), contract seal and invoice seal (collectively, the Seals) by using the re-issued business license.
  • With the settlement, Mr. Pan has returned the business license and the Seals to SINOVAC Beijing, and SINOVAC Beijing has withdrawn its claims with the Court.

Leader In Air Purification, Molekule, Launches In Europe To Deliver Clean Indoor Air To Everyone, Everywhere

Retrieved on: 
Tuesday, November 23, 2021
Air pollution, IPhone, CEO, Organic compound, Technology, Bacteria, Metro, ARE, University of Minnesota, Virus, University, Apple, Solution, Laboratory, City, Atmosphere of Earth, Lawrence Berkeley National Laboratory, Research, Influenza A virus subtype H1N1, Intertek, Allergen, European Environment Agency, United Kingdom, Atmosphere, PECO, Android, Science, IOS, Minnesota, Volatile organic compound, Pharmaceutical industry

LONDON, Nov. 23, 2021 /PRNewswire/ -- Molekule, the science company that reinvented air purification with its groundbreaking PECO technology, today announced that its award-winning air purifiers will be available to consumers in the United Kingdom and across Europe directly via Molekule's website. Molekule's mission is to destroy indoor air pollution and provide crisp, clean indoor air in homes, businesses, and beyond. Starting today, Molekule's best selling air purifiers, Air Mini+ and Air Pro, will be available for purchase throughout the region.

Key Points: 
  • Molekule's mission is to destroy indoor air pollution and provide crisp, clean indoor air in homes, businesses, and beyond.
  • Starting today, Molekule's best selling air purifiers, Air Mini+ and Air Pro, will be available for purchase throughout the region.
  • Air Mini+ and Air Pro are both cleared by the U.S. FDA for the destruction of bacteria and viruses, and Air Pro is additionally cleared for the destruction of mould.
  • In the UK and Europe, Molekule is launching its Air Pro and Air Mini+ purifiers.

Leader In Air Purification, Molekule, Launches In Europe To Deliver Clean Indoor Air To Everyone, Everywhere

Retrieved on: 
Tuesday, November 23, 2021
Air pollution, IPhone, CEO, Organic compound, Technology, Bacteria, Metro, ARE, University of Minnesota, Virus, University, Apple, Solution, Laboratory, City, Atmosphere of Earth, Lawrence Berkeley National Laboratory, Research, Influenza A virus subtype H1N1, Intertek, Allergen, European Environment Agency, United Kingdom, Atmosphere, PECO, Android, Science, IOS, Minnesota, Volatile organic compound, Pharmaceutical industry

LONDON, Nov. 23, 2021 /PRNewswire/ -- Molekule, the science company that reinvented air purification with its groundbreaking PECO technology, today announced that its award-winning air purifiers will be available to consumers in the United Kingdom and across Europe directly via Molekule's website. Molekule's mission is to destroy indoor air pollution and provide crisp, clean indoor air in homes, businesses, and beyond. Starting today, Molekule's best selling air purifiers, Air Mini+ and Air Pro, will be available for purchase throughout the region.

Key Points: 
  • Molekule's mission is to destroy indoor air pollution and provide crisp, clean indoor air in homes, businesses, and beyond.
  • Starting today, Molekule's best selling air purifiers, Air Mini+ and Air Pro, will be available for purchase throughout the region.
  • Air Mini+ and Air Pro are both cleared by the U.S. FDA for the destruction of bacteria and viruses, and Air Pro is additionally cleared for the destruction of mould.
  • In the UK and Europe, Molekule is launching its Air Pro and Air Mini+ purifiers.

Molekule Debuts First Showroom at The Village at Corte Madera in the Bay Area

Retrieved on: 
Thursday, November 18, 2021
Research, Pharmacology, CEO, Severe acute respiratory syndrome coronavirus 2, Technology, General manager, Bacteria, University of Nebraska Medical Center, Virus, Engineering, Village, PPE, SAN, University, Nebraska Medicine, Solution, Laboratory, COVID-19, University of Minnesota College of Science and Engineering, Atmosphere of Earth, Influenza A virus subtype H1N1, Pollen, Allergen, Atmosphere, University of Minnesota College of Design, PECO, FDA, College, CDC, Veterinary medicine, The Home Depot, Wildfire, Particulates, Department, Ohio State University, Volatile organic compound, Vaccine

Starting today, shoppers can purchase Air Mini+ and Air Pro purifiers from the company's pop-up store in The Village at Corte Madera, an open-air shopping center in Marin County.

Key Points: 
  • Starting today, shoppers can purchase Air Mini+ and Air Pro purifiers from the company's pop-up store in The Village at Corte Madera, an open-air shopping center in Marin County.
  • These achievements have positioned Molekule as a go-to comfort for many, making it a must-have gift this holiday season.
  • Come visit Molekule at The Village at Corte Madera, located at 1618 Redwood Hwy, Corte Madera.
  • Today, Molekule is available at Home Depot , Best Buy , Amazon , and at our mobile showroom at The Village at Corde Madera .

Preliminary Results Show SINOVAC’s COVID-19 Vaccine Demonstrates Good Safety Profile Among the Pediatric and Adolescent Population

Retrieved on: 
Tuesday, November 9, 2021
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Mumps, Influenza A virus subtype H1N1, Population, Safety, Chinese government award for outstanding self finance students abroad, Minor, Adolescence, WHO, Private Securities Litigation Reform Act, III, H5N1, Campus Biotech, Infection, NASDAQ, Ageing, EV71, Terminology, COVID-19, Research, Forward-looking statement, Program, Incidence, Pain, Headache, Company, Vaccine, Sinovac Biotech, Fever, Chickenpox, Vaccination, Hepatitis A

The results from statistics analysis under blind status indicated that CoronaVac is safe for healthy people of different races in the pediatric and adolescent population ranging from 3 to 17 years of age.

Key Points: 
  • The results from statistics analysis under blind status indicated that CoronaVac is safe for healthy people of different races in the pediatric and adolescent population ranging from 3 to 17 years of age.
  • The blind safety data analysis for this subgroup shows a good safety profile among healthy participants aged from 3 to 17 years.
  • The findings suggest that CoronaVac has a good safety profile among the healthy pediatric and adolescent population ranging from 3 to 17 years old.
  • SINOVACs COVID-19 vaccine, CoronaVac, has been granted emergency use approval or conditional marketing authorization by over 50 countries or regions worldwide.

Molekule's PECO Air Purification Technology Effectively Captures and Destroys SARS-CoV-2, the COVID-19 virus, New Study Shows

Retrieved on: 
Tuesday, September 21, 2021
University, Research, Solution, FDA, Atmosphere, Chemistry (relationship), Volatile organic compound, University of Nebraska Medical Center, Virus, Bacteria, CEO, Nebraska Medicine, SAN, COVID-19, Technology, Influenza A virus subtype H1N1, Severe acute respiratory syndrome coronavirus 2, Atmosphere of Earth, Allergen, HIV, PECO, Pharmacology, Department, Vaccine, Medical imaging, Pharmaceutical industry

PECO technology, which stands for Photo Electrochemical Oxidation, utilizes free radicals to destroy organic material in the air at a molecular level, such as viruses, bacteria, mold, chemicals (VOCs) and more.

Key Points: 
  • PECO technology, which stands for Photo Electrochemical Oxidation, utilizes free radicals to destroy organic material in the air at a molecular level, such as viruses, bacteria, mold, chemicals (VOCs) and more.
  • "Air purification technology has provided an extra layer of protection, and the testing results from the University of Nebraska demonstrate just how effective Molekule's PECO technology is at both capturing and destroying coronaviruses at a molecular level.
  • Recently, the University of Nebraska Medical Center, Department of Pharmacology & Experimental Neuroscience, tested Molekule's PECO technology using an Air Mini device.
  • Methods developed for the research allowed measurement and characterization of airborne virus detection and inactivation by air purification technologies.

New Research on SINOVAC’s COVID-19 Vaccine Shows Third Dose More Effective Against COVID-19, Including the Delta Variant

Retrieved on: 
Thursday, September 9, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases

Having a third dose of inactivated COVID-19 vaccine is more effective for COVID-19 prevention.

Key Points: 
  • Having a third dose of inactivated COVID-19 vaccine is more effective for COVID-19 prevention.
  • This study includes an in-depth exploration of the immunogenic profiles of antibodies from three and two-dose CoronaVac recipients and convalescents.
  • The above research provides a theoretical basis for a third dose of inactivated COVID-19 vaccine.
  • SINOVACs COVID-19 vaccine, CoronaVac, has been granted emergency use approval or conditional marketing authorization by over 50 countries or regions worldwide.

SINOVAC Announces COVID-19 Vaccine Approved for Emergency Use in Chile for Children and Adolescents

Retrieved on: 
Wednesday, September 8, 2021
Infectious Diseases, Biotechnology, Pharmaceutical, Health

To continue protecting the population, we have approved CoronaVac for children aged six and up," Garcia said.

Key Points: 
  • To continue protecting the population, we have approved CoronaVac for children aged six and up," Garcia said.
  • CoronaVac had been approved for emergency use in the population aged from 3 to 17 years old on May 28, 2021, in China.
  • It was also approved for use in the population aged from 12 to 17 years old by Indonesian authorities in June 2021.
  • The EV71 vaccine, an innovative vaccine developed by SINOVAC against hand foot and mouth disease caused by EV71, was commercialized in China in 2016.

SINOVAC Announces Positive Data on Booster Shots of CoronaVac®, Induces Strong Immune Response in Adult and Elderly Populations

Retrieved on: 
Tuesday, August 10, 2021
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Mumps, NASDAQ, COVID-19, Research, Chickenpox, Private Securities Litigation Reform Act, Publication, Clinical trial, Program, Campus Biotech, WHO, EV71, Safety, Profile, Chinese government award for outstanding self finance students abroad, Terminology, Incidence, Immunogenicity, CoronaVac, H5N1, Influenza A virus subtype H1N1, Forward-looking statement, Immunization, Vaccination, Hepatitis A, Company, Ageing, GMT, Vaccine, Sinovac Biotech

The publications detail findings from clinical studies on the immunogenicity, safety, and immune response of CoronaVac in two- and three-dose schedules.

Key Points: 
  • The publications detail findings from clinical studies on the immunogenicity, safety, and immune response of CoronaVac in two- and three-dose schedules.
  • The results indicate that a third booster dose of CoronaVac induces a strong immune response in healthy adults with no serious adverse reactions related to the vaccine.
  • This research provides important scientific data and supplement existing research to help policymakers develop strategies for vaccine rollout and timing of booster doses.
  • In addition, a third dose was found to be well-tolerated in elderly patient populations with no vaccine-related serious adverse events reported.

Emergency Physicians Increase their Calls for Concerns around COVID-19 Delta Variant and Support Mandate to Vaccinate Healthcare Workers

Retrieved on: 
Wednesday, July 28, 2021
Influenza A virus subtype H1N1

"While one statement alone may not shift the needle, we need to come together and focus on system-wide solutions if we're to beat this pandemic."

Key Points: 
  • "While one statement alone may not shift the needle, we need to come together and focus on system-wide solutions if we're to beat this pandemic."
  • The guidance for people who are unvaccinated remains the same: continue wear a mask until you are fully vaccinated.
  • These heightened efforts come after recent scientific evidence shows that the Delta variant behaves differently from other strains of the virus.
  • Emergency departments around the country are once again seeing a surge in severely ill patients, many of them young or unvaccinated.